Press Releases

Date Title and Summary Additional Formats
Toggle Summary Seattle Genetics to Host Conference Call and Webcast Discussion of Fourth Quarter and Year 2017 Financial Results on February 6, 2018
BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 18, 2018-- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets. Following the results announcement, company management
Toggle Summary Seattle Genetics Highlights Leadership in Expanding Field of Antibody-Drug Conjugates (ADCs) at the 36th Annual J.P. Morgan Healthcare Conference
-Continued Progress In Establishing ADCETRIS® (brentuximab vedotin) as the Foundation of Care for CD30-Expressing Lymphomas - -Two Solid Tumor ADC Programs Advancing Under Accelerated Approval Pathways- -Multiple Collaborator ADC Programs in Late-Stage Trials for Range of Tumor Types- BOTHELL,
Toggle Summary FDA Accepts Supplemental Biologics License Application and Grants Priority Review for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
-PDUFA Action Date May 1, 2018 - -Submission Based on Positive Results from the Phase 3 ECHELON-1 Clinical Trial- -FDA Previously Granted Breakthrough Therapy Designation for ADCETRIS in Frontline Advanced Hodgkin Lymphoma- BOTHELL, Wash. --(BUSINESS WIRE)--Jan. 2, 2018-- Seattle Genetics, Inc.